Hey there, it’s Vadim 👋

It’s been a few weeks since our last Bio Founder GPS podcast episode, so today we are going to remedy that 🙂

Quick update before we jump in: as Bio Founder GPS approaches its first anniversary, I finally made it official with a dedicated Bio Founder GPS LinkedIn page 🎉

I’ll be sharing podcast clips, founder resources, and more there, so if you’ve found Bio Founder GPS helpful over the past year, I’d love it if you followed the new page here. It would mean a lot!

Now, for today’s main event: I’m excited to share that recently I got to sit down with Chris Potts, CBO of Persephoni BioPartners, and Co-Founder and CEO of Monarch Therapeutics.

And by “sit down” I actually mean - sit down 🙂 This was officially the first in-person conversation on Bio Founder GPS. The first, I hope, of many.

There were a number of reasons why I was super excited to have Chris on.

First, he spent years as an IP attorney and executive inside companies like Lonza and Legend Biotech before making the jump into entrepreneurship with Monarch.

And today, he sits on both sides of the table: building and fundraising for his own company while helping Persephoni build and back other early-stage biotechs.

Naturally, that gave us no shortage of topics to chat about.

🧭 HERE’S WHAT WE COVERED:

  • Why most biotech failures aren't scientific failures, and what that means for how you spend your time as a founder

  • Where early-stage founders can find their first investors and true-believers (hint, it’s not the same VCs everyone else is chasing)

  • How to quickly qualify investors before spending valuable time pitching them

  • The overlooked IP decisions that can shape a biotech’s value years later

  • How Chris navigates the platform vs. asset debate

  • And much more - including how growing up raising hogs on a farm in Ohio shaped the way Chris thinks about building companies today

You can watch the full interview, or listen via your podcast platform of choice below.

Listen + subscribe: Spotify / Apple Podcasts / YouTube

While that’s loading for you, here are some highlights of what I took away from our conversation👇

BROUGHT TO YOU BY ADP

ADP - payroll, benefits, HR, and R&D tax credit support for early-stage biotechs.

Bio Founder GPS readers get founder-friendly pricing:

  • 20–30% lifetime discount on eligible services

  • Waived sign-on fees

  • Up to 6 months of free payroll (eligibility-based)

  • Preferred pricing on HR, compliance, and benefits tools

  • R&D tax credit setup and support (up to $500K offset against payroll taxes)

MAIN TAKEAWAYS

1. Most biotech failures are really business failures, not science failures

One of the ideas behind Persephoni is that when promising biotech companies fail, it often may not be due to the science.

Sometimes what looks like a scientific failure is actually the downstream consequence of a business decision.

Maybe the company chose the wrong development path or maybe the first clinical trial could have been designed differently. Or perhaps the financing strategy left the company without enough capital to reach the milestone it needed.

That distinction matters, especially for first-time scientist-founders.

Great science still has to sit inside a functioning company. Someone needs to build the development plan, manage vendors, think through regulatory strategy, raise capital, protect the IP, and make dozens of decisions about where scarce resources should go.

That’s part of the problem Persephoni is trying to solve through its venture studio model: putting experienced operators and infrastructure around scientists early enough that avoidable company-building mistakes don’t become fatal ones.

As Chris put it, sometimes a scientific failure is really “a disguised business failure.”

The takeaway for scientist founders? The business side isn't a distraction from the science, it's what actually protects it and ensures it gets to the people and patients that can benefit from it.

2. Your first investor may not be a “blue-chip” VC

Chris was especially candid about how difficult it can be to find the first institutional check.

There are plenty of investors willing to join a round once someone else leads it. The universe of people willing to say we believe in this enough to go first is considerably smaller.

For very early therapeutic companies, Chris suggested looking beyond the same 30 or 40 biotech VCs everyone else is chasing.

That might mean family offices, high-net-worth individuals, disease foundations, or investors with a personal connection to the problem you’re solving.

This can be particularly relevant in rare diseases or areas of significant unmet need.

If you’re working in Parkinson’s, for example, you should understand the ecosystem around organizations like the Michael J. Fox Foundation. For a smaller rare disease, there may be patient foundations, families, physicians, and KOLs who can point you toward people personally motivated to move that science forward.

The broader lesson is simple: Don’t define your investor universe by who has “biotech VC” in their LinkedIn headline.

Your first believer may come from somewhere else entirely. And in biotech, your first investors may be writing their check driven primarily by a human reason, not a scientific one.

3. Qualify investors as much as they qualify you (maybe even more)

If finding investors is the science of fundraising, then figuring out who’s actually capable of investing is the art.

To this, Chris made a point I strongly agree with: you should be interviewing investors every bit as much as they are interviewing you.

Before spending 25 minutes walking someone through your deck, understand what they are actually looking for.

When did they write their last check? What size was it? What have their last several investments looked like? Are they actively deploying capital today?

A fund’s website may say therapeutics, while its last five investments were AI drug-discovery companies. The thesis written on the website and the thesis reflected by recent checks aren’t always the same.

Chris likes to start first meetings by asking the investor to explain what they’re looking for before he starts pitching - I think that’s a great practice.

In fact, he told me some of his best first investor conversations are the ones where he never opens the pitch deck at all.

That first meeting is partly a pitch, but it’s also a qualification call. Above all else, it’s building a real, human relationship.

Your time, runway, and emotional energy are too valuable to spend months nurturing investors who were never going to write a check in the first place.

4. Non-dilutive capital is not a silver bullet

Grants are attractive for obvious reasons - you can advance the science without giving away equity, and for many academic spinouts, NIH, DoD, and foundation funding can help generate meaningful validation before institutional investors ever get involved.

But Chris highlighted an opportunity cost that founders can easily overlook:

Your patent clock keeps running.

A company can spend years successfully pursuing grants and emerge with excellent data, but considerably less life remaining on its core IP.

Eventually an investor, partner, or potential acquirer has to ask: how much exclusivity is actually left for me to buy?

Similarly, Chris raised an excellent point around geography.

Universities are also operating with constrained resources, which can affect decisions about where patents get filed. Choosing not to pursue protection in markets such as China, Japan, or Europe may save money today, but those decisions can become difficult or impossible to reverse later.

As biotech becomes increasingly global, those early filing decisions can materially affect future optionality.

None of this means founders should avoid non-dilutive capital.

But it does mean that the time-value of capital should not be overlooked.

5. Platform or asset? Think “platform to product”

Finally, we dug into a familiar challenge for bio founders: Should I pitch the platform or the asset?

One investor tells you nobody funds platforms anymore. Thirty minutes later, another tells you the asset story isn’t ambitious enough.

Chris has lived this tension from both sides. Persephoni likes companies with platform potential, while Monarch itself is built around a broader CAR-T platform with a lead program moving toward the clinic.

His framing was refreshingly straightforward:

Platforms don’t go into the clinic. Drugs do.

Chris calls the approach “platform to product.”

The broader platform can create enormous future optionality, but founders still need a clear product, indication, and credible path toward human proof.

Ideally, that first product does double duty: you’re generating evidence around the lead program while designing the development strategy so that some of the resulting data also helps validate the platform underneath it.

That way, the first asset becomes more than the first shot on goal - it becomes proof that the broader technology can work.

THAT’S A WRAP!

There was one theme that really carried across our conversation.

Chris grew up raising hogs and sheep on a family farm in Northeast Ohio, an experience he credits with developing what he calls the “farmer’s ethos”

A farm has limited resources and an endless list of things that need to get done.

Sound familiar? 🙂

Early biotech isn’t that different.

You can’t do everything. The job is to understand the resources you actually have, identify the few things most likely to get you to the next pool of resources, and keep moving.

Or, as Chris ultimately framed the question: What should I do today?

For the full conversation, including how Chris went from raising hogs in Ohio to building biotech companies, what founders should know before negotiating with a university tech-transfer office, how Persephoni approaches company building, and much more, watch the full episode here.

Resources from the conversation:

A couple of small asks before you go:

If you haven't already, hit follow on Spotify or Apple Podcasts - it genuinely helps us build momentum. And if you watch on YouTube, don't forget to subscribe and spread the word.

See you next week!

- Vadim

PS: Do you know a founder, an investor, or a subject matter expert that I should interview? If so, you know what to do 🙂

PPS: If you found this issue useful, the easiest way to support is to forward it to one founder who'd benefit. They can subscribe at biofounder.io